The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine
Abstract
Background: Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health. Methods: To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control. Results: On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later. Conclusion: The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Cited by
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Zimmermann, P., & Curtis, N. (2020) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,077
Metadata
- Authors
- Lin, J.-T., Zhang, J.-S., Su, N., Xu, J.-G., Wang, N., Chen, J.-T., Chen, X., Liu, Y.-X., Gao, H., Jia, Y.-P., Liu, Y., Sun, R.-H., Wang, X., Yu, D.-Z., Hai, R., Gao, Q., Ning, Y., Wang, H.-X., Li, M.-C., Kan, B., Dong, G.-M., An, Q., Wang, Y.-Q., Han, J., Qin, C., Yin, W.-D., & Dong, X.-P.
- Venue
- Antiviral Therapy
- Publisher
- SAGE Publications
- Published
- 2007-10
- Volume
- 12
- Issue
- 7
- Pages
- 1107-1114
- ISSN
- 1359-6535 (ISSN-L)
- 2040-2058
- OpenAlex
- W2398175096
- Cited by
- 167
- References
- 1
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine. https://app.cochat.ai/papers/10.1177/135965350701200702
- The paper
- Lin, J.-T., Zhang, J.-S., Su, N., Xu, J.-G., Wang, N., Chen, J.-T., Chen, X., Liu, Y.-X., Gao, H., Jia, Y.-P., Liu, Y., Sun, R.-H., Wang, X., Yu, D.-Z., Hai, R., Gao, Q., Ning, Y., Wang, H.-X., Li, M.-C., . . . Dong, X.-P. (2007). Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine. Antiviral Therapy. https://doi.org/10.1177/135965350701200702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.